FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

Go back to FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
(NASDAQ: FGEN) Delayed: 21.01 +0.74 (3.65%)
Previous Close $20.27    52 Week High $31.90 
Open $20.30    52 Week Low $14.38 
Day High $21.35    P/E N/A 
Day Low $20.30    EPS $0.00 
Volume 374,156